Lessons Learned from First Ten Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug Resistant Bacterial Infections at a Single Center in the US

  01 September 2020

Due to increasing multidrug resistant (MDR) infections there is an interest is assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego in June 2018.

We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials.

Author(s): Saima Aslam, Elizabeth Lampley, Darcy Wooten, Maile Karris, Constance Benson, Steffanie Strathdee, Robert T Schooley
Healthy Patients  

Registration now open:

International Masterclass AMR 29 SEP delivered digitally: 2 = 1!


  • Science, Health-Economic & Societal impact
  • Global causes and global solutions
  • Bottom-up, interactive approach
  • International Experts involved

Offered online!

Register today >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!